Benralizumab: 15 agencies, 2017–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 8.8 years, from 17 Nov 2017 at AWMSG (Wales) to 20 Sep 2026 at NYE METODER (Norway).
NYE METODER (Norway) changed its position: not recommended on 27 Jan 2019, recommended by 20 Sep 2026, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for benralizumab.
The file is active: 14 of 31 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for benralizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 31 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess benralizumab, on 17 Nov 2017; CIPM (Spain) did not open a file until 21 May 2025 — a wide spread of 7.5 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 9 years in total.
12 of the 15 agencies here assessed benralizumab more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
benralizumab has been through 15 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for benralizumab reads 18 recommended, 5 restricted, 4 not recommended and 2 deferred to NICE, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 13 Jul 2026 | Add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis. | accepted | source |
| HAS (France) | 10 Sep 2025 | Indication extension | SMR insufficient | source |
| NICE (England) | 3 Sep 2025 | NICE TA1096 | published appraisal | source |
| PHARMAC (New Zealand) | 17 Jun 2025 | Eosinophilic granulomatosis with polyangiitis (EGPA) - widening access, 1st line | PTAC advice: High | source |
| ZIN (Netherlands) | 4 Jun 2025 | Advies - vergoed benralizumab (Fasenra®) voor de behandeling van een bepaalde vorm van vasculitis (EGPA) | reimbursed | source |
26 further decisions for benralizumab, across 15 agencies, are not shown here. They include the most recent record on file, 20 Sep 2026 from NYE METODER (Norway); its outcome is in the subscriber dataset. They link to 21 further source documents.
Related molecules
- mepolizumab — same ATC class R03D — Obstructive airway diseases
- omalizumab — same ATC class R03D — Obstructive airway diseases
- tezepelumab — same ATC class R03D — Obstructive airway diseases
- montelukast — same ATC class R03D — Obstructive airway diseases
- depemokimab — same ATC class R03D — Obstructive airway diseases
- roflumilast — same ATC class R03D — Obstructive airway diseases
Coverage: 31 decisions for benralizumab from 15 agencies, 2017 to 2026. Data to 7 Sep 2026. ATC class R03D — Obstructive airway diseases. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.